-
Mashup Score: 1Plain language summary: the potential role of afatinib in treating people with NRG1 gene fusion-positive cancer - 3 year(s) ago
This plain language summary reports the findings of a case series exploring the role of afatinib in treating NRG1 gene fusion-positive cancer.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Plain language summary: the potential role of afatinib in treating people with NRG1 gene fusion-positive cancer - 3 year(s) ago
This plain language summary reports the findings of a case series exploring the role of afatinib in treating NRG1 gene fusion-positive cancer.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This plain language summary reports the findings of a case series exploring the role of #afatinib in treating NRG1 gene fusion-positive cancer. https://t.co/rw1Tm1brSA @FutureOncol_FSG
-
-
Mashup Score: 0
The GioTag study assessed how drugs called afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. Resistance mutations in our genes can lead to resistance to specific treatments, meaning that drugs no longer work. Patients in the current study all initially received afatinib treatment before they…
Source: Future OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Find out about the GioTag study, exploring sequential #Afatinib + #Osimertinib in #EGFR #NSCLC , in this #PLSP from @FutureOncol_FSG https://t.co/WceovZTUZW https://t.co/rv30fcjHun
-
-
Mashup Score: 0
The GioTag study assessed how drugs called afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. Resistance mutations in our genes can lead to resistance to specific treatments, meaning that drugs no longer work. Patients in the current study all initially received afatinib treatment before they…
Source: Future OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Don't miss out on reading this Plain Language Summary of the #GioTag study on sequential #Afatinib + #Osimertinib in #EGFR #NSCLC https://t.co/wrhvmmxRzc #LCAM #lcsm #lungcancerawarenessmonth https://t.co/LWRx1ywuLA
-
-
Mashup Score: 2Phase I Study of Afatinib and Selumetinib in Patients with KRAS‐Mutated Colorectal, Non‐Small Cell Lung, and Pancreatic Cancer - 4 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase I Study of Afatinib and Selumetinib in Patients with KRAS‐Mutated Colorectal, Non‐Small Cell Lung, and Pancreatic Cancer #Afatinib #Selumetinib #KRAS #ColorectalCancer #NonSmallCellLungCancer #PancreaticCancer https://t.co/pkN68o8PWP https://t.co/zG48CV9wpq
-
-
Mashup Score: 1
Afatinib is a treatment option for patients with SCC of the lung progressing on chemotherapy who are ineligible for immunotherapy, particularly those with ERBB family genetic aberrations. Afatinib has a predictable and manageable tolerability profile, and long-term treatment may be well tolerated.
Source: EClinicalMedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
📢NEW RESEARCH: #Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell #carcinoma of the #lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial Available #openaccess 👇 https://t.co/YMA1iAYhnY
-
-
Mashup Score: 1Afatinib Exerts Immunomodulatory Effects by Targeting the Pyrimidine Biosynthesis Enzyme CAD - 4 year(s) ago
Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune checkpoint blockade (ICB) therapies show no additional effect. This raises questions regarding whether EGFR-TKIs attenuate ICB-enhanced CD8+ T lymphocyte function. Here we show that the EGFR-TKI afatinib suppresses CD8+ T lymphocyte proliferation, and we identify CAD, a key enzyme of de novo pyrimidine…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study by Tu et al reveals EGFR tyrosine kinase inhibitor #afatinib has immunomodulatory effects on CD8+ T lymphocytes which may help guide treatment timing for combined targeted therapy and #immunotherapy. https://t.co/iUWjnoutF0 https://t.co/GhtieSK6rO
-
-
Mashup Score: 2
The GioTag study assessed how drugs called afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. Re…
Source: www.futuremedicine.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Make sure to read the latest plain language summary from @FutureOncol_FSG @Boehringer to gain insights into the final results from the #GioTag study https://t.co/WIvMRpPJrw #Afatinib, #Osimertinib #nsclc https://t.co/z1LPq96DTN
-
-
Mashup Score: 0Home - Oncology Central - 4 year(s) ago
At Oncology Central we are dedicated to advancing oncology by publishing trusted, engaging and insightful resources for the global oncology community.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Discover more about the use of #Afatinib for the treatment of #NSCLC #LungCancer harboring uncommon EGFR mutations in the latest @VJofBiomedicine Publication Perspective: https://t.co/SwcjKcSkbY
-
-
Mashup Score: 0
A recent publication perspective investigates observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Watch the latest Publication Perspective from @VJofBiomedicine summarizing a recent observational study of sequential #Afatinib and #Osimertinib in EGFR+ #NSCLC #LungCancer now: https://t.co/Yjd37AKXOs
-
Find out details of a case series exploring the role of #afatinib in treating NRG1 gene fusion-positive cancer. https://t.co/tIiE6SKt9M @FutureOncol_FSG